Probably we're going to end up as Pfizer as the victor, ... We believe we'll probably end up there, but the ratio will probably be sweetened too.

I wish he hit it a little harder. Victor would've caught it.

I'm very pleased with the outcome and the results. I probably could have thrown 10 or 15 more, if I wanted to, but overall I'm really happy with how I threw.

It's probably from over-use. It's going to be sore for a while. It's probably chronic.

We're probably younger than we have been, but we still believe we have made improvements.

I think investors need to be careful because there are some significant antitrust overlaps ... The antitrust review in the U.S. and Europe will be extremely detailed and we do not expect the transaction to close before February.